CHOLINERGIC STRATEGIES IN THE TREATMENT OF ALZHEIMERS-DISEASE

被引：28

作者：

DAVIDSON, M ^{[1
]}

STERN, RG ^{[1
]}

BIERER, LM ^{[1
]}

HORVATH, TB ^{[1
]}

ZEMISHLANI, Z ^{[1
]}

MARKOFSKY, R ^{[1
]}

MOHS, RC ^{[1
]}

机构：

[1] VET ADM MED CTR, BRONX, NY 10468 USA

来源：

ACTA PSYCHIATRICA SCANDINAVICA | 1991年 / 83卷

关键词：

ACETYLCHOLINESTERASE INHIBITOR; CHOLINERGIC AGONIST; TREATMENT; ALZHEIMERS DISEASE;

D O I：

10.1111/j.1600-0447.1991.tb03109.x

中图分类号：

R749 [精神病学];

学科分类号：

100205 ;

摘要：

Since the identification of the cholinergic deficit, strategies aimed at enhancing cholinergic neurotransmission have dominated the field of pharmacology in Alzheimer's disease (AD). These strategies include increasing acetylcholine precursor availability, delaying synaptic degradation and stimulating muscarinic receptors. Although most clinical trials report mild symptomatic improvements in some patients, support for large-scale clinical use of cholinomimetics in AD is not yet available. This article presents the most representative clinical trials, discusses the limitations of the cholinergic strategies and suggests future directions in the treatment of AD.

引用

页码：47 / 51

页数：5

共 37 条

[1] THE CHOLINERGIC HYPOTHESIS - A HISTORICAL OVERVIEW, CURRENT PERSPECTIVE, AND FUTURE-DIRECTIONS
BARTUS, RT
DEAN, RL
PONTECORVO, MJ
FLICKER, C
[J]. ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1985, 444 (MAY) : 332 - 358
[2] LOSS OF NEURONS OF ORIGIN OF THE ADRENERGIC PROJECTION TO CEREBRAL-CORTEX (NUCLEUS LOCUS CERULEUS) IN SENILE DEMENTIA
BONDAREFF, W
MOUNTJOY, CQ
ROTH, M
[J]. NEUROLOGY, 1982, 32 (02) : 164 - 168
[3] BIOCHEMICAL ASSESSMENT OF SEROTONERGIC AND CHOLINERGIC DYSFUNCTION AND CEREBRAL ATROPHY IN ALZHEIMERS-DISEASE
BOWEN, DM
ALLEN, SJ
BENTON, JS
GOODHARDT, MJ
HAAN, EA
PALMER, AM
SIMS, NR
SMITH, CCT
SPILLANE, JA
ESIRI, MM
NEARY, D
SNOWDON, JS
WILCOCK, GK
DAVISON, AN
[J]. JOURNAL OF NEUROCHEMISTRY, 1983, 41 (01) : 266 - 272
[4] ANTICHOLINESTERASE ACTIVITY OF A NEW CARBAMATE, HEPTYLPHYSOSTIGMINE, IN VIEW OF ITS USE IN PATIENTS WITH ALZHEIMER-TYPE DEMENTIA
BRUFANI, M
MARTA, M
POMPONI, M
[J]. EUROPEAN JOURNAL OF BIOCHEMISTRY, 1986, 157 (01): : 115 - 120
[5] MUSCARINIC AGONIST THERAPY OF ALZHEIMERS-DISEASE - A CLINICAL-TRIAL OF RS-86
BRUNO, G
MOHR, E
GILLESPIE, M
FEDIO, P
CHASE, TN
[J]. ARCHIVES OF NEUROLOGY, 1986, 43 (07) : 659 - 661
[6] PHYSOSTIGMINE AND ARECOLINE - EFFECTS OF INTRAVENOUS INFUSIONS IN ALZHEIMER PRESENILE-DEMENTIA
CHRISTIE, JE
SHERING, A
FERGUSON, J
GLEN, AIM
[J]. BRITISH JOURNAL OF PSYCHIATRY, 1981, 138 (JAN) : 46 - 50
[7] Davidson M, 1987, Biol Psychiatry, V22, P112, DOI 10.1016/0006-3223(87)90139-9
[8] 4-AMINOPYRIDINE IN THE TREATMENT OF ALZHEIMERS-DISEASE
DAVIDSON, M
ZEMISHLANY, Z
MOHS, RC
HORVATH, TB
POWCHIK, P
BLASS, JP
DAVIS, KL
[J]. BIOLOGICAL PSYCHIATRY, 1988, 23 (05) : 485 - 490
[9] DAVIES P, 1976, LANCET, V2, P1403
[10] DAVIS DM, 1989, FORUM MATH, V1, P1

← 1 2 3 4 →